Efficacy, acceptability and safety of Internet-delivered psychological therapies for fibromyalgia syndrome: A systematic review and meta-analysis of randomized controlled trials

被引:33
|
作者
Bernardy, K. [1 ]
Klose, P. [2 ]
Welsch, P. [3 ]
Haeuser, W. [3 ,4 ,5 ]
机构
[1] Ruhr Univ, BG Univ Hosp Bergmannsheil GmbH, Dept Pain Med, Bochum, Germany
[2] Univ Duisburg Essen, Kliniken Essen Mitte, Fac Med, Dept Internal & Integrat Med, Duisburg, Germany
[3] Hlth Care Ctr Pain Med & Mental Hlth, Saarbrucken, Germany
[4] Klinikum Saarbrucken, Dept Internal Med 1, Saarbrucken, Germany
[5] Tech Univ Muunchen, Dept Psychosomat Med & Psychotherapy, Munich, Germany
关键词
COGNITIVE-BEHAVIORAL THERAPY; UPDATED GUIDELINES 2017; CHRONIC PAIN; CRITERIA; QUALITY;
D O I
10.1002/ejp.1284
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
This systematic review aimed at evaluating the efficacy, acceptability and safety of Internet-based psychological therapies (IPTs) in fibromyalgia syndrome (FMS). Clinicaltrials.gov, Cochrane Library, MEDLINE, PsycINFO and SCOPUS were searched from inception to January 2018. Randomized controlled trials (RCTs) comparing IPTs with controls were analysed. Primary outcomes were >= 50% pain relief, disability, negative mood, acceptability and safety at end of therapy and at 6-month follow up. Effects were summarized by a random effects model using risk differences (RD) or standardized mean differences (SMD) with 95% confidence intervals (CI). Six RCTs using different types of Internet-based cognitive-behavioural therapies [ICBTs] (acceptance-based; exposure-based; traditional) with 493 patients were included. At the end of treatment, ICBTs were superior to controls (waiting list, attention control, treatment as usual) in reducing negative mood (SMD -0.51 [95% CI -0.87 to -0.15]) (moderate quality evidence) and disability (SMD -0.56 [95% CI -1.00 to -0.13]) (moderate quality evidence). There were no statistically significant differences between ICBTs and controls in pain relief of 50% or greater (RD 0.09 [95% CI -0.02 to 0.20] (moderate quality evidence) and acceptability (moderate quality evidence). No data on safety and any outcomes at long-term follow-up compared to controls were found. The data available did not allow statistical comparisons between unguided and guided ICBTs and of ICBTs versus traditional face-to-face therapies. ICBTs provided a clinically relevant benefit over control interventions in reducing negative mood and disability at the end of treatment. Significance Internet-delivered cognitive behavioural therapies provided a clinically relevant benefit in reducing negative mood and disability in patients with FMS at the end of treatment if compared to waiting list, treatment as usual and attention controls.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 50 条
  • [21] Efficacy of acupuncture in fibromyalgia syndrome-a systematic review with a meta-analysis of controlled clinical trials
    Langhorst, Jost
    Klose, Petra
    Musial, Frauke
    Irnich, Dominik
    Haeuser, Winfried
    RHEUMATOLOGY, 2010, 49 (04) : 778 - 788
  • [22] Efficacy of hypnosis/guided imagery in fibromyalgia syndrome - a systematic review and meta-analysis of controlled trials
    Bernardy, Kathrin
    Fueber, Nicole
    Klose, Petra
    Haeuser, Winfried
    BMC MUSCULOSKELETAL DISORDERS, 2011, 12
  • [23] Efficacy of EMG- and EEG-Biofeedback in Fibromyalgia Syndrome: A Meta-Analysis and a Systematic Review of Randomized Controlled Trials
    Glombiewski, Julia Anna
    Bernardy, Kathrin
    Haeuser, Winfried
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [24] Safety and efficacy of perampanel in epilepsy: A systematic review and meta-analysis of randomized controlled trials
    Lavu, Alekhya
    Aboulatta, Laila Nabil Mahmoud Helmy
    Abou-Setta, Ahamed M.
    Aloud, Basma
    Askin, Nicole
    Rabbani, Rasheda
    Shouman, Walid
    Zarychanski, Ryan
    Eltonsy, Sherif
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 329 - 330
  • [25] Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
    Guedeney, Paul
    Giustino, Gennaro
    Sorrentino, Sabato
    Claessen, Bimmer E.
    Camaj, Anton
    Kalkman, Deborah N.
    Vogel, Birgit
    Sartori, Samantha
    De Rosa, Salvatore
    Baber, Usman
    Indolfi, Ciro
    Montalescot, Gilles
    Dangas, George D.
    Rosenson, Robert S.
    Pocock, Stuart J.
    Mehran, Roxana
    EUROPEAN HEART JOURNAL, 2022, 43 (07) : E17 - E25
  • [26] Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials
    Singh, Awadhesh Kumar
    Singh, Ritu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (02) : 183 - 190
  • [27] SAFETY AND EFFICACY OF NITAZOXANIDE ON DIARRHEA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Hashan, Mohammad
    Elhusseiny, Khaled
    Le, Huu
    Hien Tong Thi Thu
    Thuan Minh Tieu
    Low, Soon
    Thai Le Ba Nghia
    Nhu, Mai
    Eid, Peter
    Nguyen, Phuong
    Loc Quang Le
    Abed, Mohammed
    Le Huu Nhat Minh
    Hirayama, Kenji
    Nguyen Tien Huy
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 369 - 370
  • [28] Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    Li, Zengbin
    Jiang, Zeju
    Zhang, Yingxuan
    Huang, Xiaotian
    Liu, Qiong
    CANCERS, 2020, 12 (06)
  • [29] THE SAFETY AND EFFICACY OF RESMETIROM FOR MASH: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Jaber, Fouad
    Altobaishat, Obieda
    Amin, Ahmed
    Bataineh, Omar
    Youssef, Rana
    Sallam, Yazan
    Turkmani, Mustafa
    Abuelazm, Mohamed
    HEPATOLOGY, 2024, 80
  • [30] Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials
    Pereira, Mable
    Franco, Ancy Jenil
    Chintharala, Karthik
    Vieira, Ana Carolina Putini
    de Jesus, Ana Carolina Ventura de Santana
    Lajczak, Pawel
    Alhwaishel, Khaled
    Castaneda, Mario Saul Lira
    Weba, Elizabet Taylor Pimenta
    Reich, Kristian
    INFLAMMOPHARMACOLOGY, 2025,